Blood Pressure-Lowering Therapy by Sudano, Isabella et al.









Sudano, Isabella ; Osto, Elena ; Ruschitzka, Frank
Abstract: Extensive evidence demonstrates that lowering blood pressure can substantially reduce the risk
of atherosclerotic cardiovascular disease and death.In light of the latest 2018 European Society of Cardi-
ology/European Society of Hypertension Joint Guidelines, we summarize the current recommendations
about lifestyle intervention strategies, pharmacotherapy, and device-based treatments for the manage-
ment of arterial hypertension. Special attention is given to direct effects exerted by some antihypertensive
drugs targeting vascular wall cell components that are involved in the pathogenesis of atherosclerosis.
DOI: https://doi.org/10.1007/164_2020_372






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Sudano, Isabella; Osto, Elena; Ruschitzka, Frank (2020). Blood Pressure-Lowering Therapy. In: Barrett,
James E. Handbook of Experimental Pharmacology. New York: Springer, Epub ahead of print.
DOI: https://doi.org/10.1007/164_2020_372
Blood Pressure-Lowering Therapy





2.2 Reduce Alcohol Intake
2.3 Weight Loss and Avoidance of Overweight and Obesity
2.4 Regular Physical Activity
3 Pharmacological Therapy for the Treatment of Arterial Hypertension
3.1 Who Should Be Treated with Pharmacological Therapy?
3.2 Choice of Initial Antihypertensive Agents
3.3 Combination Therapy
3.4 Direct Effects of Antihypertensive Drugs on Atherosclerosis
4 Perspectives of Future Antihypertensive Therapy
4.1 Unresolved Medical Needs





Extensive evidence demonstrates that lowering blood pressure can substantially
reduce the risk of atherosclerotic cardiovascular disease and death.
The original version of this chapter was revised. A correction to this chapter can be found at
https://doi.org/10.1007/164_2020_410
I. Sudano · F. Ruschitzka (*)
Department of Cardiology, University Heart Center Zurich, Zürich, Switzerland
e-mail: frank.ruschitzka@usz.ch
E. Osto
Department of Cardiology, University Heart Center Zurich, Zürich, Switzerland
Institute of Clinical Chemistry, University of Zurich, University Hospital Zurich, Zürich,
Switzerland
# The Author(s) 2020, corrected publication 2020
Handbook of Experimental Pharmacology, https://doi.org/10.1007/164_2020_372
In light of the latest 2018 European Society of Cardiology/European Society
of Hypertension Joint Guidelines, we summarize the current recommendations
about lifestyle intervention strategies, pharmacotherapy, and device-based
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1 Introduction
Continuous progress in understanding the epidemiology, pathophysiology, and
pharmacology of arterial hypertension has consistently improved the possibility of
an efficient and safe treatment of elevated blood pressure (BP).
Extensive evidence demonstrates that lowering BP can substantially reduce the
risk of cardiovascular disease (CVD) and death with similar proportional reductions
across various population subgroups. Every 10 mmHg systolic BP reduction signifi-
cantly diminished the risk of major CVD events (RR 0.80, 95% CI 0.77–0.83),
coronary heart disease (0.83, 0.78–0.88), stroke (0.73, 0.68–0.77), heart failure
(0.72, 0.67–0.78), and all-cause mortality (0.87, 0.84–0.91) (Ettehad et al. 2016).
Arterial hypertension is characterized by structural and functional changes in
blood vessels, which lead to increased arterial stiffness, vascular inflammation,
endothelial dysfunction, fatty streaks, early atherosclerotic plaque, plaque progres-
sion, and plaque rapture. Vice versa, arterial stiffness, endothelial dysfunction, and
vascular inflammation may also contribute to increased BP. Several lifestyle
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interventions and drugs lowering BP were demonstrated to improve endothelial
function, decrease arterial stiffness and vascular inflammation, and ultimately pre-
vent the development and/or progression of atherothrombosis.
After exclusion of the main causes of a secondary hypertension, lifestyle
modifications should be suggested as BP and cardiovascular risk lowering strategy
to every patient with arterial hypertension. However, sooner or later, most patients
diagnosed with arterial hypertension will require a pharmacological therapy.
According to the 2018 ESC/ESH Guidelines (Williams et al. 2018), the necessity
of a pharmacological therapy will be defined by the grade of arterial hypertension
(see Table 1), the cardiovascular risk, and the presence of hypertension-mediated
organ damage or concomitant diseases such as a history of cardiovascular events,
diabetes mellitus, or chronic kidney disease. The 2018 Guidelines suggest as general
rule to reduce office BP below 140/90 mmHg aiming to reach a BP around
130/80 mmHg; see Table 1.
The ultimate goal of antihypertensive therapy is the prevention of cardiovascular
events. The higher the absolute cardiovascular risk, the more likely it is that a patient
will benefit from a more aggressive BP goal. However, although cardiovascular
events generally decrease with more intensive lowering of BP, the risk of adverse
effects, cost, and patient inconvenience increase as more medication is added
(Ettehad et al. 2016; Williams et al. 2018). See Fig. 1.
This recommendation together with good clinical judgment and shared decision-
making between patients and care providers should guide our BP-lowering therapy.
2 Non-pharmacological Therapy
Treatment of hypertension should always include non-pharmacological therapy
(Fig. 1) (Williams et al. 2018).
Table 1 From ESC/ESH guidelines for hypertension, Eur Heart Journal 2018 (#ESC/ESH 2018)
Table 3. Classification of office blood pressurea and definitions of hypertension gradeb
Category Systolic (mmHg) Diastolic (mmHg)
Optimal <120 and <80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 hypertension 140–159 and/or 90–99
Grade 2 hypertension 160–170 and/or 100–109
Grade 3 hypertension 180 and/or 110
Isolated systolic hypertensionb 140 and <90
BP blood pressure, SBP systolic blood pressure
The same classification is used for all ages from 16 years
aBP category is defined according to seated clinic BP and by the highest level of BP, whether
systolic or diastolic
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The ESC/ESH Guidelines (Williams et al. 2018) suggested the following lifestyle
changes as contributors for reducing BP and cardiovascular risk to the majority of
patients with arterial hypertension: healthy diet including dietary sodium restriction
and moderation of alcohol consumption, overweight reduction, regular physical
activity, and cessation of consumption of any product containing tobacco or
nicotine.
2.1 Salt Restriction
In general, a healthy diet should avoid any excess: moderate sodium reduction is
associated with a decrease in BP in hypertensive and normotensive individuals of a
maximum of 4.8–2.5 mmHg systolic and 1.9–1.1 mmHg diastolic, respectively
(He and MacGregor 2003).
Young patients with hypertension usually are salt-resistant, while older patients
as well as obese individuals or patients with diabetes mellitus and chronic kidney
disease are characterized by increased salt sensitivity (Weinberger 1996).
Evidence supporting very strong reduction of salt intake is weak. The effect of
reduced dietary sodium on cardiovascular event rates remains unclear (Bibbins-
Domingo et al. 2010; He et al. 2011; He and MacGregor 2011; Taylor et al. 2011).
Prospective cohort studies have reported an overall increased risk of mortality and
cardiovascular events on high sodium intake, but to date, no prospective randomized
controlled trial has provided definitive evidence about the optimal sodium intake to
minimize cardiovascular events and mortality. However, it was reported that reduc-
ing sodium intake below 3 g of sodium per day further reduced BP, but paradoxically
was associated with an increased risk of all-cause and cardiovascular mortalities in
both the general population and in hypertensive patients, suggesting a J-curve
phenomenon (Mente et al. 2016).
Increased potassium intake is associated with BP reduction and may have a
protective effect, thereby modifying the association between sodium intake, BP,
and CVD. Increasing potassium intake (e.g., including high intake of vegetables and
fruits in the diet) could be a problem in patients with diabetes and chronic kidney
disease and cannot be applied to all hypertensive patients (Bernabe-Ortiz et al. 2020;
Binia et al. 2015; Mente et al. 2016; Miller et al. 2016).
Therefore, every patient with arterial hypertension independently of his/her
sodium sensitivity should reduce the sodium consumption and avoid processed
and frozen food, which frequently is rich in salt.
2.2 Reduce Alcohol Intake
For a long time, positive linear associations between alcohol consumption, BP,
prevalence of hypertension, and cardiovascular risk have been established.
The Prevention and Treatment of Hypertension Study (PATHS) investigated the
effects of reduced alcohol consumption on BP; the intervention group had a modest
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1.2/0.7 mmHg lower BP than the control group at the end of the 6-month follow-up
period. A meta-analysis of 56 epidemiological studies suggested that reduction of
alcohol consumption, even for light-moderate drinkers, might be beneficial for
cardiovascular health (Holmes et al. 2014). Binge drinking can cause strong
increases of BP (Mancia et al. 2013).
Hypertensive men and women, who drink alcohol, should be advised to limit
their consumption to 14 units and 8 units per week, respectively (one unit is equal to
125 mL of wine or 250 mL of beer). Alcohol-free days during the week and
avoidance of binge drinking are also recommended (Williams et al. 2018).
2.3 Weight Loss and Avoidance of Overweight and Obesity
Weight loss in overweight or obese individuals leads to a significant reduction in BP,
independently of exercise and dietary sodium restriction (Appel et al. 2006; Cohen
and Gadde 2019), and has multiple beneficial effects against pathologic factors
leading to high BP and to end-organ damage in this patient population (Cohen and
Gadde 2019).
Weight loss is associated with decreased intra-abdominal pressure exerted on
vessels by the excessive visceral fat deposition. Another beneficial effect of weight
loss is the amelioration of insulin resistance, which is associated with renal sodium
reabsorption and increased sympathetic tone in obesity. Moreover, chronic inflam-
mation associated with overweight/obesity promotes vascular aging, favoring the
onset of hypertension. Inflammation also contributes to arterial stiffness and impairs
the physiologic anti-contractile effect of perivascular adipocytes on adjacent small
arteries (Virdis et al. 2015; Aghamohammadzadeh et al. 2013). Decrease in body
weight with lifestyle management, although effective in the short term, is difficult to
sustain in the longer-term follow-up. Indeed, the overall efficacy of lifestyle
interventions in reducing cardiovascular outcomes has been questioned by the
results of the Action for Health in Diabetes (Look AHEAD) Study (Look, Ahead
Research Group et al. 2013; Semlitsch et al. 2016). Currently, the most effective
pharmacological treatments against obesity include glucagon like peptide-1 (GLP-1)
receptor agonists and bariatric surgery. GLP-1 receptor agonists, in particular
liraglutide, are cornerstones in antidiabetic therapy, which also have shown positive
effects in reducing BP and CVD mortality (Helmstadter et al. 2020; Pi-Sunyer et al.
2015; Mingrone et al. 2015). Liraglutide is currently available also as weight-loss
medication in obese patients without diabetes and has promising effects improving
hypertension and cardiovascular risk profile over 1-year treatment (Pi-Sunyer et al.
2015; Fonseca et al. 2014; le Roux et al. 2017).
Bariatric surgery has a sustained effect on weight loss, which is superior to
pharmacological and lifestyle modifications. Considerable weight loss after bariatric
surgery corresponds to high rates of remission of hypertension (Pareek et al. 2019).
The GATEWAY trial showed that a reduction of 30% of the total number of
antihypertensive medications while maintaining controlled blood pressure occurred
in 83.7% of the patients randomized to receive the Roux-en-Y gastric bypass plus
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antihypertensive medical therapy compared with only 12.8% patients from the
control group with pharmacological therapy alone. Indeed, remission of hyperten-
sion was present in almost 50% of patients randomized to gastric bypass, whereas no
patient randomized to control therapy was free of antihypertensive drugs at
12-month follow-up (Schiavon et al. 2018).
2.4 Regular Physical Activity
Epidemiological studies suggest that regular aerobic physical activity is beneficial
for both reducing BP and decreasing CVD event rates and mortality (Franklin et al.
2020; Williams et al. 2018). As a result and along with the notion that “more exercise
is better,”more and more normotensive and hypertensive adults have increased their
participation in high-intensity interval training or competitive long distance endur-
ance events. However, the quality and intensity of the physical activity is very
important. Recent evidence suggests that beyond a safe upper limit, exercise may
result in deleterious cardiovascular adaptations. For instance, exercise-induced
hypertension and the race distances may contribute to the occurrence of myocardial
fibrosis detectable by MRI in asymptomatic triathletes (Tahir et al. 2018).
Aerobic endurance training, dynamic resistance training, and isometric training
reduce resting systolic BP and diastolic BP by mean 3.5/2.5, 1.8/3.2, and 10.9/
6.2 mmHg, respectively, in general populations. Regular physical activity of lower
intensity and duration lowers BP less than moderate- or high-intensity training, but is
associated with at least a 15% decrease in mortality in cohort studies (Rossi et al.
2012). Thus, the current ESC/EHS Guidelines recommend at least 30 min of
moderate dynamic exercise (walking, jogging, cycling, or swimming) on 5–7 days
per week (Williams et al. 2018). The impact of isometric exercises on BP and CVD
risk is less well-established, although it can be part of a comprehensive treatment
regimen (Chrysant 2010).
3 Pharmacological Therapy for the Treatment of Arterial
Hypertension
Current evidence suggests that treatment and gradual control of hypertension by the
use of the major classes of antihypertensive drugs exert positive effects on athero-
sclerosis. Randomized controlled trials provided robust evidence that five drug
classes lower BP and prevent CVD events. They are therefore recommended by
the 2018 ESC/ESH Guidelines (Williams et al. 2018) for the treatment of hyperten-
sion: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor
blockers (ARBs), beta-blockers, calcium channel blockers (CCBs), and diuretics
(thiazides and thiazide-like diuretics such as chlorthalidone and indapamide). ACE-I
or ARBs alone or in combination with a calcium antagonist or a diuretic (thiazide-
like to be preferred to thiazide) are considered for the first-line treatment. The use of
beta-blockers is limited to special indications.
Blood Pressure-Lowering Therapy
3.1 Who Should Be Treated with Pharmacological Therapy?
The benefits of antihypertensive therapy are clear in the majority of patients with
arterial hypertension, but still controversial in subgroups. They include patients with
Grade 1 hypertension but without manifest CVD, patients with white coat or masked
hypertension and low cardiovascular risk, patients with an estimated 10-year cardio-
vascular risk<10%, and patients older than 75 years of age who are non-ambulatory
or living in nursing homes.
Randomized trials demonstrated that treating hypertension with any antihyper-
tensive therapy reduces cardiovascular morbidity and mortality. According to the
ESC/ESH Guidelines, antihypertensive drug therapy should be initiated without any
delay in patients with hypertension Grades 2 or 3 or after some time under
non-pharmacological therapy in individuals with very high cardiovascular risk and
Grade 1 or high-normal BP (Fig. 1). The decision to initiate drug therapy should be
individualized and involve shared decision-making between patient and provider.
3.2 Choice of Initial Antihypertensive Agents
Multiple studies and meta-analyses conclude that the degree of BP reduction rather
than the kind of antihypertensive medication is the major determinant of reduction in
cardiovascular risk in patients with hypertension (Ettehad et al. 2016).
However, not all antihypertensive drugs are equally effective in reducing cardio-
vascular events and only few reduced mortality (van Vark et al. 2012).
Recommendations for the use of specific classes of antihypertensive medications
are based upon clinical trial evidence of decreased cardiovascular risk, BP-lowering
efficacy, safety, and tolerability. Most patients with hypertension will require more
than one BP medication to reach their BP goal. As the consequence, the new
guideline for treatment of hypertension suggests to use combination therapy at
early stage and, if possible, a fixed-dose single-pill combination medication to
improve adherence (Williams et al. 2018). Having multiple available classes of BP
medications, practitioners and clinicians can individualize therapy based upon
individual patient characteristics and preferences.
The following drugs are suggested for the start of monotherapy or combination
therapy of arterial hypertension:
– ACE inhibitors
– ARBs
– Long-acting CCBs (most often a dihydropyridine such as amlodipine)
– Thiazide-like or thiazide-type diuretics
The previous 2013 Guidelines (Mancia et al. 2013) favored monotherapy for the
start of treating hypertension. However, only a minority of patients reach the target
blood pressure level under monotherapy, and the combination of two drugs is much
more efficient than increasing the dose of a single drug (Williams et al. 2018).
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Therefore, the current 2018 Guidelines limit the start of monotherapy to low-risk
patients with stage 1 hypertension whose SBP is <150 mmHg, very high-risk
patients with high-normal BP, or frail older patients; see Table 1.
3.3 Combination Therapy
Single-agent therapy will not adequately control BP in most patients whose baseline
systolic BP is 15 mmHg or more above their goal. Combination therapy with drugs
from different classes has a substantially greater BP-lowering effect than doubling
the dose of a single agent (Wald et al. 2009).
When more than one agent is needed to control BP, a therapy with a long-acting
ACE inhibitor or ARB in combination (fix if this is possible) with a long-acting
dihydropyridine CCB or a diuretic is the first choice. Combination of an ACE
inhibitor or ARBs with a thiazide diuretic is considered less beneficial, when
hydrochlorothiazide instead of thiazide-like diuretic (chlorthalidone or indapamide)
is used (Burnier et al. 2019; Williams et al. 2018). ACE inhibitors and ARBs should
not be used together.
Chlorthalidone and indapamide have been used in several RCTs showing cardio-
vascular benefits, and these agents are more potent per milligram in lowering BP and
have a longer duration of action compared with hydrochlorothiazide without any
evidence of more side effects (Williams et al. 2018).
As such, even if head-to-head RCTs are missing, this data suggests that thiazide-
like diuretics such as chlorthalidone and indapamide should be preferred over
classical thiazide diuretics (e.g., hydrochlorothiazide and bendrofluazide) (Williams
et al. 2018; Burnier et al. 2019; Roush et al. 2015).
The Danish Cancer Registry and the Danish Prescription Registry examined the
association between the use of hydrochlorothiazide (HCTZ) and the risk of basal cell
carcinoma, squamous cell carcinoma, and nodular melanoma (Pedersen et al. 2018a,
2018b, 2019). These two case-control studies showed that high cumulative doses of
HCTZ (>50 g) are associated with a dose-dependent increase in the risk of
non-melanoma skin cancer, but not of melanoma. The increase of risk was only
small for squamous cell carcinoma and negligible for basal cell carcinoma. These
studies have several limitations including the investigation of a pale-skinned popu-
lation and the lack of information on genetic predisposition, sun habits, and ultravi-
olet exposure. Moreover, the risk reduction of death due to lower BP by HCTZ was
much stronger than the small risk increase for squamous cell carcinoma by HCTZ. In
general, statistically significant associations from observational studies do not prove
any causal relationship.
The next step is the combination of RAAS blocker, Ca antagonists, and thiazide/
thiazide-like diuretics.
If BP is not sufficiently controlled by this triple combination therapy, a mineralo-
corticoid receptor (MR) antagonist (i.e., spironolactone or eplerenone) may be added
(Williams et al. 2015).
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In patients with difficult-to-treat/resistant hypertension, a beta-blocker, an alpha-
blocker, or a direct arterial vasodilator could be added.
Generally, concomitant use of beta-blockers and non-dihydropyridine CCBs
should be avoided, as both drug classes reduce heart rate.
3.4 Direct Effects of Antihypertensive Drugs on Atherosclerosis
Apart from lowering blood pressure and thereby removing an important risk factor,
some antihypertensive drugs appear to exert direct effects on vascular cells that are
involved in the pathogenesis of atherosclerosis.
3.4.1 ARBs and ACE Inhibitors
ARBs and ACE inhibitors directly affect the renin-angiotensin-aldosterone system
(RAAS), by blocking the binding of angiotensin II (Ang II) to the AT1 receptor and
decreasing the production of Ang II, respectively. Hypertension promotes and
accelerates the atherothrombotic process via inflammatory mechanisms linked to
activation of oxidative stress by Ang II, which subsequently leads to endothelial
dysfunction and development of atherogenic lesions and plaques. Endothelial dys-
function is observed in the early stages of atherosclerosis. A healthy endothelium
induces vasodilatation and has antioxidant and anti-thrombotic effects. The dysfunc-
tional endothelium releases less of nitric oxide (NO) and other protective molecules,
has a disrupted redox balance, and acquires pro-constrictive and pro-thrombotic
phenotypes (Flammer et al. 2012; Sudano et al. 2011). A dysfunctional endothelium
has been associated with cardiovascular risk factors including diabetes mellitus or
impaired glucose metabolism, hypertension, cigarette smoking, dyslipidemia, obe-
sity, and/or metabolic syndrome (Flammer et al. 2012; Sudano et al. 2011).
RAAS antagonists, as well as some dihydropyridine CCBs, possess ancillary and
synergistic effects that increase NO bioavailability, reduce oxidative stress, and
suppress inflammatory responses, thereby improving both endothelial activity and
vascular function (Safar and Smulyan 2007; Sudano et al. 2011; Taddei et al. 2002).
3.4.2 Diuretics
Among the diuretics, thiazide-like diuretics such chlorthalidone and indapamide but
not hydrochlorothiazide were found to improve endothelial function (Dell'Omo et al.
2005; Vinereanu et al. 2014). Indapamide also reduces arterial stiffness (Agnoletti
et al. 2013).
3.4.3 Calcium Antagonists
Dihydropyridine CCBs lower BP mainly through vasodilation and reduction of
peripheral resistance. Several clinical studies have demonstrated that they have
clinical benefits in patients with CVD. Some studies have indicated that
dihydropyridine CCBs have anti-atherogenic effects beyond their BP-lowering
effects (Silva et al. 2019; Sudano et al. 2011). In fact, in several animal models,
dihydropyridine CCBs were found to suppress the formation of atherosclerotic
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lesions. It is well-known that the production of reactive oxygen species (ROS) is
involved in the progression of atherosclerosis by stimulating the production of
inflammatory factors such as chemokines, cytokines, and adhesion molecules
(Mason 2002; Ishii et al. 2012). Dihydropyridine CCBs can suppress ROS genera-
tion and subsequent inflammatory actions in vascular cells and arterial walls.
Furthermore, several reports have revealed that dihydropyridine CCBs suppress
the expression of adhesion molecules, thereby inhibiting monocyte adhesion to
endothelial cells, which is an early step in the pathogenesis of atherosclerosis.
Dihydropyridine CCBs also suppress proliferation and migration of smooth muscle
cells both in vitro and in vivo (Mason 2002; Ishii et al. 2012). In macrophages,
dihydropyridine CCBs decrease cholesterol accumulation and intracellular choles-
terol esterification and increase cholesteryl ester hydrolysis. Moreover,
dihydropyridine CCBs suppress the expression of matrix metalloproteinases,
which affects the stability of atheromatous plaques. Interestingly, recent studies
have revealed that the anti-atherosclerotic effects of dihydropyridine CCBs are
mediated, at least in part, via the activation of peroxisome proliferator-activated
receptor-γ (Ishii et al. 2012).
3.4.4 Beta-Blockers
In general, beta-blockers usually do not have any effect on endothelial function and
atherothrombosis. The only exception is nebivolol, thanks to its high selectivity as
beta1-blocker. Nebivolol inhibits the proliferation of human coronary smooth mus-
cle and endothelial cells (Brehm et al. 2001). The specific vasorelaxant properties of
nebivolol are mediated by endothelium-dependent NO release and antioxidant
activity (do Vale et al. 2018). Unfortunately, nebivolol treatment in patients with
non-obstructive coronary artery disease was associated with greater plaque progres-
sion and constrictive remodeling as compared to atenolol (Hung et al. 2016).
Carvedilol, a nonselective blocker with additional adrenergic receptor antagonist
activity, has also been shown to exert beneficial actions against endothelial dysfunc-
tion through its antioxidant effects (Bank et al. 2007), although the molecular
mechanisms have not yet been fully clarified (Virdis et al. 2011).
3.4.5 Mineralocorticoid Receptor Antagonists
The MR antagonists, spironolactone and eplerenone, have been shown to reduce
morbidity and mortality, in part, by blunting the adverse effects of aldosterone on
endothelial function and inflammation involved in the development and
complications of atherosclerosis. Recent evidence highlight that pharmacological
blockade or genetic deletion of endothelial MR blunt vascular inflammation includ-
ing expression of adhesion molecules, leukocyte-endothelial interactions, and
plaque inflammation. Of note, in preclinical studies endothelial MR inhibition is
protective only in male, but not in female mice (Moss et al. 2019). Thus, gender- and
sex-specific actions of the MR in vascular function and atherosclerosis, so far still
poorly investigated, will deserve future attention also in the clinical setting (Shen
et al. 2017). Sympathetic hyperactivity with rising catecholamine levels and adren-
ergic receptors stimulation is a common feature of many CVDs, including
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hypertension. This is associated with endothelial NO synthase uncoupling and a
pro-constrictive vascular phenotype on adjacent small arterial vessel wall
components, such as smooth muscle and endothelial cells. Activation of MR signal-
ing in the perivascular adipose tissue surrounding small arteries contributes to
β-adrenoceptor overstimulation. Thus, MR antagonists targeting the endothelium
and the perivascular adipocytes surrounding small arteries may achieve a dual
benefit in hypertension with involvement of sympathetic over-activation, as, for
instance, in overweight and obesity (Victorio et al. 2016).
4 Perspectives of Future Antihypertensive Therapy
4.1 Unresolved Medical Needs
Despite large evidence confirming the importance of lowering BP and the availabil-
ity of many effective and well-tolerated antihypertensive drugs, BP control rate is
unfortunately not as high as it should. This is, at least in part, related to poor
adherence to lifelong antihypertensive therapy but also, in a minority of patients,
due to “difficult to treat” or “resistant” hypertension.
According to the guidelines, resistant or difficult-to-treat hypertension is defined
as: blood pressure that is not controlled to goal despite adherence to an appropriate
regimen of three antihypertensive drugs of different classes (including a diuretic) in
which all drugs are prescribed at suitable antihypertensive doses (Williams et al.
2018). Pseudo-resistance as well as secondary causes of hypertension should be
excluded before this diagnosis is made.
Pseudo-resistance results from some or all of the following (Williams et al. 2018):
• Inaccurate blood pressure measurement (e.g., use of an inappropriately small
blood pressure cuff, not allowing a patient to rest quietly before taking readings)
• Poor adherence to blood pressure medications
• Poor adherence to lifestyle and dietary approaches to lower blood pressure
• Suboptimal antihypertensive therapy, due either to inadequate doses, an inappro-
priate drug combination, or exclusion of a diuretic from the antihypertensive
regimen
• White coat hypertension
• Extracellular volume expansion
• Increased sympathetic activation
• Ingestion of substances that can elevate the blood pressure, such as nonsteroidal
anti-inflammatory drugs (NSAIDs) or stimulants
• Secondary or contributing causes of hypertension
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4.2 New Drug Developments
Recent research has not yielded major advances in treatment of hypertension: no
new targets were identified for development of antihypertensive drugs. In fact, trends
show a dramatic slowing of research and development for novel blood pressure-
lowering drugs. The reasons are manifold: the field is crowded with relatively
effective drugs; there is a lack of major new discoveries and targets; and there are
many challenges in developing blockbuster drugs. A short look in clinicaltrial.gov
shows that while the development of new classes of antihypertensive drugs is
apparently waning, the most current activities by big pharmaceutical companies
focused on developing new combination pills, including fixed-dose combination
drugs with the exception of a new ARB (fimasartan) and the compound AGSCT101,
which is actually tested versus carvedilol. Fimasartan is an Ang II receptor antago-
nist with selectivity for the AT-1 receptor subtype, developed in 2012 by a Korean
company (Boryung Pharmaceutical) as an oral antihypertensive drug (Fimasartan
2011; Chi et al. 2011). Fimasartan reduced BP with a good tolerability profile in a
large-scale observational population study – Safe-KanArb (Park et al. 2013). The
K-MetS study (Park et al. 2017) included 10,601 patients with metabolic syndrome
and evaluated long-term effects of fimasartan on major adverse cardiovascular
outcomes.
A recent study evaluated the effects of fimasartan and amlodipine therapy on
carotid atherosclerotic plaque inflammation using 18F-fluorodeoxyglucose positron
emission tomography imaging. Both drugs similarly decreased carotid atheroscle-
rotic plaque inflammation in patients with acute coronary syndrome (Oh et al. 2019).
Concerning AGSCT101, a new antihypertensive drug developed by Ahn-Gook
Pharmaceuticals Co., Ltd., the details are scarce. The Phase III Clinical Trial to
Evaluate the Antihypertensive Effect of AGSCT101 Versus Carvedilol in Patient
with Stage 1 to 2 Essential Hypertension is described in clinicaltrial.gov. Unfortu-
nately, data about mechanism of action of this drug and status of recruiting of the
described study are missing.
4.3 Device Therapy
Various device-based therapies such as renal denervation, carotid baroreceptor
stimulation, creation of an arteriovenous fistula, or endovascular carotid body
modification have emerged, principally targeted at the treatment of resistant
hypertension.
Most data are available for renal denervation. The principle of renal denervation
is to destroy some of the sympathetic nerves around the renal artery leading to lower
sympathetic nervous activity and lower BP. The first results on renal denervation
were obtained with devices using radiofrequency application in the open label SY
MPLICITY HTN-1 and SYMPLICITY HTN-2 trials, along with several case series
and observational studies. The SYMPLICITY HTN-3 trial proved safety, but was
unable to show efficacy of renal denervation using a radiofrequency catheter when
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compared with sham treatment in patients with severe resistant hypertension on
multiple medications (Williams et al. 2018). Post hoc analyses of the SYMPLICITY
HTN-3, however, revealed important information concerning patient selection,
difference in adherence to antihypertensive medication in the treatment groups, a
higher use of antihypertensive drugs in the sham group, as well as technical failure in
performing renal denervation, which led to a revision of renal denervation technol-
ogy and technique. Based on this background, several novel, sham-controlled
studies have been conducted and are, in part, published. SPYRAL HTN-OFF
MED (Townsend et al. 2017; Bohm et al. 2020), SPYRAL HTN-ON MED
(Kandzari et al. 2018), as well as RADIANCE-HTN SOLO (Azizi et al. 2018)
showed significant and consistent reductions in BP, both office and ambulatory, in
patients with and without concomitant antihypertensive.
The SPYRAL HTN-ONMED was recently published and showed the superiority
of catheter-based renal denervation compared with a sham procedure to safely lower
BP in the absence of antihypertensive medications (Bohm et al. 2020). Catheter-
based renal denervation is superior to a sham procedure to safely lower BP in the
absence of antihypertensive medications.
Less data are available about the effect of carotid baroreceptor stimulation and
endovascular carotid body modification both techniques aiming to reduce BP
through reduction of sympathetic tone and obtained by creation of an arteriovenous
fistula. Concerning carotid baroreceptor stimulation, the first-generation device
reduced BP in controlled and uncontrolled clinical trials, while controlled clinical
trials proving efficacy in BP reduction do not exist for the currently available second-
generation carotid sinus stimulator (Jordan et al. 2019; Heusser et al. 2020).
Some, mostly uncontrolled, studies suggest that other techniques such as
baroreflex amplification and carotid body modulation may lead to reduction of BP
in patients with difficult-to-treat hypertension. However more evidence on safety
and efficacy from ongoing large randomized sham-controlled trials is needed before
baroreflex amplification and carotid body modulation can be implemented in routine
clinical practice (Groenland and Spiering 2020).
Last, but not least, the possibility to safely reduce BP in patients with uncon-
trolled hypertension by creating a central iliac arteriovenous anastomosis was tested.
The ROX CONTROL HTN study (Lobo et al. 2015) tested this hypothesis using the
novel arteriovenous ROX Coupler (ROX Medical, San Clemente, CA, USA).
This small study (44 patients treated and 39 patients in the standard of care group)
enrolled and showed that creation of an arteriovenous anastomosis was associated
with significantly reduced BP.
The actual ESC/ESH Guidelines do not recommend the use of any device-based
therapies for the routine treatment of hypertension, unless in the context of clinical
studies and RCTs (Williams et al. 2018).
Nevertheless, device-based therapy for hypertension is a fast-moving field, and
new data especially data from study evaluating renal denervation are expected in the
near future and could change this recommendation.
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5 Conclusion
Hypertension represents one of the most important modifiable risk factors for stroke,
heart failure, myocardial infarction, and chronic kidney disease, contributing signifi-
cantly to the global burden of CVD.
The initial assessment of a patient with hypertension is essential for choosing
effective therapy. All cardiovascular risk factors as well as hypertension-mediated
target organ damage and presence of comorbidities should be taken into account.
The treatment of hypertension should focus on the overall health of the patient,
focusing on reducing the risk of future cardiovascular events.
For a long-lasting adherence, it is important that patients are actively involved in
the process of choosing the best BP-lowering strategies.
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